According to research from WHO in 2017, it is estimated that 1 in 10 medical products circulating in low- and middle-income countries is either substandard or falsified, which indicated that people are taking medicines that fail to treat or prevent disease(1). Apart from increased morbidity and mortality from substandard and falsified medicines, it is also a financial loss to individuals and health systems that purchase these products(1,2).